Zantac Relaunches With New Name and Ingredient After Recall Due to Increased Cancer Risk
In April 2020, the Food and Drug Administration (FDA) issued a recall of all prescription and over-the-counter (OTC) versions of ranitidine, more commonly known as Zantac, due to an increased cancer risk. Recently, the medication relaunched with a new name and ingredient: Zantac 360 (famotidine). The oral tablet is available in two strengths (10 mg … Continue reading Zantac Relaunches With New Name and Ingredient After Recall Due to Increased Cancer Risk
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed